Carlsmed has launched its aprevo technology platform for cervical fusion surgeries in the U.S. Surgeons involved in aprevo’s clinical evaluation will also present early clinical data at the Cervical Spine Research Society (CSRS) 53rd annual meeting this week.

The aprevo Cervical interbody system expands the company’s personalized spine platform, which merges artificial intelligence (AI)-driven preoperative planning with 3D-printed, patient-specific implants tailored to patient anatomy and pathology. The cervical platform builds on the aprevo lumbar platform’s success, which Carlsmed said has shown lower complication rates and fewer revision surgeries compared to standard stock implants.

Dr. Andrew Chan, MD, at Columbia University/New York-Presbyterian Och Spine Hospital said the personalization is the next frontier in cervical spine surgery. Dr. Chan serves as director of minimally invasive scoliosis surgery and director of neurosurgical spine research there.

“With aprevo Cervical we’re able to preoperatively plan in three dimensions and deliver a device that’s matched to each patient’s unique anatomy,” Dr. Chan told the press. “That level of precision enhances how we correct alignment while helping broaden access to anterior cervical procedures for more complex patients.”

Over 370,000 cervical fusion surgeries were performed in the U.S. this year, Carlsmed cited. The need for tech to support improved alignment and anatomical fit in patients with poor bone quality continues to grow. The company said early clinical experience demonstrates that efficient workflow integration, precise implant fit with maximized endplate coverage, and, when compared with stock implants, an ability to achieve planned sagittal and coronal alignment goals.

“We are excited to bring the aprevo platform to cervical fusion procedures, representing an important milestone in our mission to transform spine surgery,” said Mike Cordonnier, chairman and CEO of Carlsmed. “With positive clinical feedback from our first 50+ cases, strong reimbursement support and accelerating demand, we believe our cervical system has the potential to redefine the standard of care in cervical spine surgery.”

Last month, the company appointed Jennifer Kamocsay as chief legal officer and secretary. Kamocsay has more than two decades of corporate legal experience as in-house counsel across life science and technology sectors at Akoya Biosicences, Rubius Therapeutics Inc., and Progress Software Corporation.

Learn more about Carlsmed’s patient-specific spinal fusion tech in this feature article!